

## **Idiopathic Intracranial Hypertension and Cardiovascular Diseases Risk in the United Kingdom Women: An Obesity-Adjusted Risk Analysis Using Indirect Standardization**

Ahmed Y. Azzam<sup>1, 2, 3#\*</sup>, Mahmoud M. Morsy<sup>1, 4#</sup>, Mohamed Hatem Ellabban<sup>5</sup>, Ahmed M. Morsy<sup>6</sup>, Adham Adel Zahran<sup>6</sup>, Mahmoud Nassar<sup>7, 8</sup>, Omar S. Elsayed<sup>1</sup>, Adam Elswedy<sup>1</sup>, Osman Elamin<sup>9</sup>, Ahmed Saad Al Zomia<sup>10</sup>, Hana J. Abukhadajah<sup>11</sup>, Hammam A. Alotaibi<sup>12</sup>, Oday Atallah<sup>13</sup>, Mohammed A. Azab<sup>14</sup>, Muhammed Amir Essibayi<sup>2, 15</sup>, Adam A. Dmytriw<sup>16, 17</sup>, Mohamed D. Morsy<sup>18</sup>, David J. Altschul<sup>2, 15</sup>

- 1- Faculty of Medicine, October 6 University, 6<sup>th</sup> of October City, Giza, Egypt.
- 2- Montefiore-Einstein Cerebrovascular Research Lab, Albert Einstein College of Medicine, Bronx, NY, USA.
- 3- Director of Clinical Research and Clinical Artificial Intelligence, American Society for Inclusion, Diversity, and Health Equity (ASIDE), Delaware, USA.
- 4- Clinical Research Fellow, American Society for Inclusion, Diversity, and Health Equity (ASIDE), Delaware, USA.
- 5- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- 6- Kasr Alainy Faculty of Medicine, Cairo University Hospitals, Cairo University, Cairo, Egypt.
- 7- Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, USA.
- 8- Founder, American Society for Inclusion, Diversity, and Health Equity (ASIDE), Delaware, USA.
- 9- Department of Neurosurgery, Jordan Hospital, Amman, Jordan.
- 10- College of Medicine, King Khalid University, Abha, Saudi Arabia
- 11- Medical Research Center, Hamad Medical Corporation, Doha, Qatar.
- 12- Ophthalmology Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
- 13- Department of Neurosurgery, Hannover Medical School, Hannover, Germany.
- 14- Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, OH, USA.
- 15- Department of Neurological Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- 16- Neuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Harvard University, Boston, MA, USA
- 17- Neurovascular Centre, Divisions of Therapeutic Neuroradiology & Neurosurgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.
- 18- College of Medicine, King Khalid University, Abha, Saudi Arabia.

**# Denotes Equal Contribution as First Author**

**Corresponding Author\*:**

Ahmed Y. Azzam, MD, MEng,

Montefiore-Einstein Cerebrovascular Research Lab,

Albert Einstein College of Medicine,

Bronx, NY, USA

Email Address: [ahmedyazzam@gmail.com](mailto:ahmedyazzam@gmail.com)

## **Abstract:**

**Introduction:** Idiopathic intracranial hypertension (IIH) is associated with increased cardiovascular disease (CVD) risk, but the relative contributions of obesity versus IIH-specific factors remain unclear. This study aims to disentangle the effects of obesity and IIH on stroke and CVD risk, building upon previous research suggesting a two-fold increased risk of cardiovascular events in women with IIH compared to BMI-matched controls.

**Methods:** We conducted an obesity-adjusted risk analysis using Indirect Standardization analysis based on Adderley et al. study which utilized data from a cohort of 2,760 women with IIH and 27,125 matched healthy controls from The Health Improvement Network (THIN) database. We employed innovative statistical models to adjust for the confounding effects of obesity, estimating the risk of ischemic stroke and cardiovascular disease attributable to IIH independent of obesity. Four distinct models were used to elucidate the complex interrelationships between IIH, obesity, and CVD risk.

**Results:** Our analysis revealed that IIH confers additional cardiovascular risk beyond that attributed to obesity alone. Risk ratios for various cardiovascular outcomes were consistently elevated across models comparing IIH patients to controls within the same obesity strata. A striking synergistic effect between IIH and obesity was observed, with the composite CVD risk reaching a risk ratio of 6.19 (95% CI: 4.58-8.36,  $p < 0.001$ ) in obese IIH patients compared to non-obese controls.

**Conclusions:** This study provides compelling evidence for a nuanced relationship between IIH, obesity, and cardiovascular risk. IIH appears to confer substantial cardiovascular risk independent of obesity, necessitating a paradigm shift in IIH management to encompass comprehensive cardiovascular risk mitigation. Further research is needed to elucidate the underlying mechanisms and develop targeted interventions for this unique patient population.

**Keywords:** Idiopathic Intracranial Hypertension; Pseudotumor Cerebri; Stroke; Ischemic Stroke; Cardiovascular Disease

## 1. Introduction:

Idiopathic intracranial hypertension (IIH) is a condition characterized by elevated intracranial pressure of unknown etiology, typically manifesting as papilledema with associated risks of visual loss and chronic disabling headache [1]. The incidence and economic burden of IIH are rising in parallel with global obesity trends [2]. While obesity is a well-established risk factor for IIH, with over 90% of patients being obese [3], the relationship between IIH and cardiovascular disease (CVD) risk remains poorly understood.

Adderley et al. conducted a retrospective case-control population-based matched controlled cohort study using 28 years of data from The Health Improvement Network (THIN) database in the United Kingdom, THIN database is a longitudinal primary care database containing anonymized electronic health records from over 17 million patients in the United Kingdom, provides researchers with comprehensive clinical data for epidemiological studies and healthcare research. [4]. Their study suggested that women with IIH have a two-fold increased risk of cardiovascular events compared to BMI-matched controls. However, the mechanisms underlying this elevated risk and the relative contributions of obesity versus IIH-specific factors remained unclear.

Building upon Adderley et al.'s [4] findings, our study aims to disentangle the effects of obesity and IIH on stroke risk specifically. Obesity is a known independent risk factor for stroke, with an average hazard ratio (HR) of 2.29 reported in large-scale evidence [5]. By adjusting for this obesity-related risk, we seek to isolate the potential contribution of IIH itself to stroke incidence.

Recent evidence suggests that IIH may be characterized by a unique profile of androgen excess affecting cerebrospinal fluid dynamics [6]. Androgen excess has been implicated as a key driver of increased cardiovascular risk in other conditions such as polycystic ovary syndrome [7, 8]. This raises the possibility that IIH may confer additional cardiometabolic risk beyond that attributable to obesity alone.

The prevalence and incidence of IIH have increased dramatically in recent years. Mollan et al. reported a tripling of IIH incidence in the UK between 2005 and 2017, from 2.3 to 7.8 per 100,000 person-years [2]. This rising disease burden underscores the urgent need to better understand and mitigate the long-term health risks associated with IIH.

Our study employs a novel methodological approach to simulate the predicted ischemic stroke and cardiovascular events in both IIH and control groups as if they had normal weight. By applying the established HR for obesity to adjust the observed events, we aim to estimate the risk of ischemic stroke and cardiovascular disease attributable to IIH independent of obesity. This

approach assumes that the effect of obesity on stroke and cardiovascular disease risk remains constant over the study period and is independent of IHH status.

Understanding the relationship between IHH and their associated risks, independent of obesity, has important clinical implications. If IHH itself confers additional cardiovascular risk, it may warrant more aggressive management of modifiable risk factors and earlier implementation of preventive strategies in this patient population. Furthermore, elucidating the mechanisms underlying this potential association could reveal new therapeutic targets for reducing cardiovascular morbidity in IHH.

Our study aims to build upon the foundational work of Adderley et al. [4] to further investigate the complex interplay between IHH, obesity, and the associated risks. By employing innovative statistical methods to adjust for the confounding effects of obesity, we aim to provide crucial insights into the cardiovascular implications of IHH and inform evidence-based management strategies for this increasingly prevalent condition.

## **2. Methods:**

Building upon the foundational work of Adderley et al. [4], we conducted a retrospective analysis using data from their paper which was originally obtained through The Health Improvement Network (THIN), a large UK primary care database. Our study focused on women with IHH and matched controls, aiming to elucidate the independent effect of IHH on stroke and cardiovascular risks, distinct from the influence of obesity.

### *2.1. Study Population and Data Source:*

We utilized the cohort established by Adderley et al. [4], comprising 2,760 women with IHH and 27,125 matched controls. Participants were identified from THIN database records spanning January 1, 1990, to January 17, 2018. Controls were matched to IHH patients based on age, body mass index (BMI), and sex, with up to 10 controls per IHH case.

### *2.2. Outcome Measures:*

Our primary outcome of interest was the incidence of composite CVD, heart failure, ischemic heart disease (IHD), ischemic stroke, transient ischemic attack (TIA), hypertension, and type 2 diabetes mellitus. We extracted the relevant data from the corresponding paper, following the coding and identification methods described by Adderley et al [4].

### *2.3. Statistical Analysis:*

We extended the original analysis to estimate the independent effect of IHH on stroke and cardiovascular risks, accounting for the confounding effect of obesity. Our approach involved indirect standardization and adjustment with the application of a standardized morbidity ratio (SMR) approach [9-13], adapted to account for obesity as a confounding variable in relationship

with IHH in women around the United Kingdom. To estimate the incidence of events in both the IHH and control cohorts under a hypothetical scenario of normal weight, we employed an adjustment method based on the average HR for obesity contributing to the event risk in women compared to healthy weight women in 13-year interval from the literature. This approach operates under the assumption that the HR remains constant throughout the 13-year study period and that the impact of obesity on the estimated events is independent of IHH status.

Initially, we calculated the observed HR for each event in the IHH group compared to the control group. Subsequently, we adjusted this observed HR by obesity HR to estimate the HR for IHH independent of obesity.

Based on the current evidence, the average estimated HR of obesity contributing to composite CVD is 2.89 [14-20]. For obesity, ischemic stroke, and TIA risk, it is estimated around HR= 1.72 [14, 17, 21-27]. For obesity and heart failure risk, it is estimated around HR= 2.61 [28-34]. For obesity and hypertension risk, it is estimated around HR= 2.09 [35-41]. For obesity and IHD risk, it is estimated around HR= 1.8 [14, 15, 17, 19, 21, 42, 43]. And for obesity and type 2 diabetes mellitus risk, it is estimated to be around HR= 4.0 [44-51].

We calculated the HR for each event in the IHH group compared to the control group through the following equation:

$$HR = (IHH \text{ events} / IHH \text{ total}) / (Control \text{ events} / Control \text{ total})$$

We then adjusted this observed HR by the established HR for obesity in association with the potential risk to estimate the HR for IHH independent of obesity:

$$Adjusted \text{ HR} = Observed \text{ HR} / Obesity \text{ HR}$$

Using this adjusted HR, we predicted the number of events in both groups under normative weight conditions:

For the IHH group:

$$Predicted \text{ IHH events} = (Adjusted \text{ HR} \times Control \text{ events} \times IHH \text{ total}) / Control \text{ total}$$

For the control group:

$$Predicted \text{ Control events} = Control \text{ events} / Obesity \text{ HR}$$

Using this adjusted HR, we then calculated the predicted number of events in both the IHH and control groups under the assumption of normal weight. This was accomplished by applying the adjusted HR to the control group event rate and scaling for the respective group sizes. For the control group, we divided the observed events by obesity HR to estimate events under normal weight conditions.

This method allows for a comparative analysis of events risk between IHH and control populations, while attempting to control the confounding effect of obesity. It provides insight

into the potential independent risk associated with IHH and allows for estimation of event rates under hypothetical normal weight conditions.

#### *2.4. Ethical Considerations:*

This study adhered to the ethical approval obtained by Adderley et al. [4] from the NHS South-East Multicenter Research Ethics Committee. We did not involve direct analysis of the dataset rather than building customized statistical modeling based on the provided data and metrics from Adderley et al. research paper [4].

### **3. Results:**

#### *3.1. Baseline Characteristics:*

The original retrospective cohort study by Adderley et al. [4] encompassed 29,885 participants, stratified into 2,760 (9.2%) women with idiopathic intracranial hypertension (IHH) and 27,125 (90.8%) controls. The incident cohort comprised 48.2% and 46.7% of the IHH and control groups, respectively. Both cohorts were predominantly under 60 years of age (98.1% IHH, 95.2% control), with identical median ages of 32.1 years (IQR: 25.62-42.00 IHH, 25.71-42.06 control). Socioeconomic status, assessed via Townsend Deprivation Quintiles, showed a comparable distribution between groups, with a slight overrepresentation of controls in the least deprived quintiles. Smoking habits differed significantly: the IHH cohort exhibited higher rates of current smoking (30.8% vs 22.6%) and lower rates of non-smoking (46.5% vs 55.5%).

Anthropometric data revealed marginally higher median BMI in the IHH group (34.80, IQR: 29.30-40.30) compared to controls (34.30, IQR: 29.00-39.70). Notably, both groups demonstrated a high prevalence of obesity (BMI >30), affecting 62.6% and 60.9% of the IHH and control cohorts, respectively. Comorbidity profiles and pharmacological interventions showed distinct patterns. The IHH cohort demonstrated a higher prevalence of migraine (21.0% vs. 11.9%), hypertension (13.8% vs. 9.2%), and marginally increased rates of lipid-lowering medication use (6.5% vs. 5.8%). Furthermore, baseline cardiovascular morbidity was more pronounced in the IHH group, with elevated rates of ischemic heart disease (1.3% vs. 0.9%) and ischemic stroke/TIA (1.7% vs 0.7%). Interestingly, type 2 diabetes mellitus prevalence was slightly lower in the IHH cohort (4.7% vs. 5.2%), **Table 1**.

#### *3.2. Statistical Analysis:*

In this analysis, we employed four distinct statistical models to elucidate the complex interrelationships between IHH, obesity, and cardiovascular disease (CVD) risk. These models were strategically designed to disentangle the individual and combined effects of IHH and obesity on cardiovascular outcomes.

Model 1 (Obese IHH vs Obese Control) was constructed to isolate the effect of IHH within an obese population, effectively controlling for the confounding factor of adiposity. Model 2 (Obese

IIH vs Non-obese Control) provided a comprehensive view of the combined impact of IIH and obesity compared to individuals without either condition. Model 3 (Non-obese IIH vs Obese Control) offered a unique perspective, juxtaposing the cardiovascular risks associated with IIH in non-obese individuals against those attributed to obesity alone. Model 4 (Non-obese IIH vs. Non-obese Control) isolated the impact of IIH in a non-obese population, providing critical insights into the condition's effects independent of obesity, **Table 2**.

Our findings revealed a nuanced and clinically significant relationship between IIH, obesity, and cardiovascular risk. In Model 1 **Figure 1**, IIH was consistently associated with elevated risks across all measured outcomes. The risk ratios (RR) ranged from 1.54 (95% CI: 1.27-1.86,  $p < 0.001$ ) for type 2 diabetes mellitus to 2.28 (95% CI: 1.62-3.21,  $p < 0.001$ ) for stroke/TIA. This uniform pattern of risk elevation suggests that IIH confers additional cardiovascular risk beyond that attributed to obesity alone, a finding of relevance in clinical risk stratification.

Model 2, **Figure 2** demonstrated even more pronounced risk elevations, with the composite CVD risk reaching a striking RR of 6.19 (95% CI: 4.58-8.36,  $p < 0.001$ ). This marked increase suggests a potential synergistic effect between IIH and obesity on cardiovascular health, which may have significant implications for patient management and therapeutic interventions. Notably, the risk for heart failure in this model was particularly elevated (RR 5.75, 95% CI: 3.17-10.42,  $p < 0.001$ ), highlighting the need for vigilant cardiac monitoring in obese IIH patients.

Interestingly, Model 3, **Figure 3**, presented a more complex picture. The non-significant risk ratios for most outcomes in this model suggest that non-obese individuals with IIH may not have significantly different cardiovascular risks compared to obese individuals without IIH. This finding underscores the profound impact of obesity on cardiovascular health, potentially rivaling or even overshadowing the effects of IIH in certain contexts. Of note in this model was the significantly reduced risk of type 2 diabetes mellitus in non-obese IIH patients compared to obese controls (RR 0.40, 95% CI: 0.28-0.57,  $p < 0.001$ ). This intriguing paradox may offer valuable insights into the underlying pathophysiology of both conditions and warrants further mechanistic investigation.

Model 4, **Figure 4** provided robust corroboration of IIH as an independent risk factor, with significant risk elevations observed across all outcomes in non-obese IIH patients compared to non-obese controls. The composite CVD risk in this model (RR 2.18, 95% CI: 1.41-3.39,  $p < 0.001$ ) closely mirrored that observed in Model 1, further supporting the notion that IIH confers cardiovascular risk independent of obesity status. This finding has important implications for the management of non-obese IIH patients, who may be at underappreciated cardiovascular risk.

Ranking the cardiovascular risks for IIH patients based on our data reveals the highest risk ratios in Model 2, with the following hierarchy: composite CVD (RR 6.19) > heart failure (RR 5.75) > stroke/TIA (RR 3.93) > ischemic heart disease (RR 3.76). This stratification underscores the critical importance of addressing both IIH and obesity in our highest-risk patients and may



inform the development of targeted screening and intervention protocols. The data on type 2 diabetes mellitus warrant special consideration. The 6.14-fold increased risk (95% CI: 4.90-7.70,  $p < 0.001$ ) observed in obese IHH patients compared to non-obese controls (Model 2) is particularly striking. This marked elevation, coupled with the paradoxical risk reduction in non-obese IHH patients (Model 3), suggests a complex interplay between IHH, obesity, and metabolic dysfunction. These findings raise intriguing questions about potential shared pathophysiological mechanisms and may open new avenues for research into the neuroendocrine aspects of IHH. Hypertension, a known risk factor for both CVD and IHH progression, showed a consistent pattern of elevated risk across Models 1, 2, and 4. However, the reduced risk observed in Model 3 (RR 0.77, 95% CI: 0.61-0.97,  $p = 0.03$ ) adds another layer of complexity to our understanding of the relationship between IHH, obesity, and blood pressure regulation.

#### **4. Discussion:**

Our obesity-adjusted risk analysis using indirect standardization analysis of the intricate relationship between IHH, obesity, and cardiovascular disease risk provides groundbreaking insights that not only corroborate but substantially extend the seminal work of Adderley et al [4]. By employing innovative statistical models to disentangle the complex interplay between IHH and obesity, we have unveiled a multifaceted paradigm of cardiovascular risk that challenges current understanding and opens new avenues for targeted interventions.

The consistent elevation of risk ratios across Models 1 and 4, which compare IHH patients to controls within the same obesity strata, strongly suggests a distinct pathophysiological process intrinsic to IHH that exacerbates cardiovascular vulnerability. This finding aligns with emerging research on the neuroendocrine and metabolic perturbations in IHH. Recent metabolomic profiling by O'Reilly MW et al [6]. revealed a unique signature of altered androgen metabolism in cerebrospinal fluid (CSF) of IHH patients, characterized by elevated levels of testosterone and androstenedione. This androgen excess may represent a crucial link between IHH and cardiovascular risk through multiple mechanisms, including vascular dysfunction, inflammatory modulation, and metabolic dysregulation. Duckles and Miller [52] demonstrated that testosterone could induce vasoconstriction through both genomic and non-genomic pathways, potentially contributing to hypertension and altered cerebrovascular autoregulation in IHH.

The chronic elevation of intracranial pressure (ICP) characteristic of IHH may have direct and indirect effects on cardiovascular function. Recent work by Wardlaw et al. [53] on the glymphatic system and intracranial fluid dynamics suggests that altered CSF flow and clearance in IHH may impair the removal of metabolic waste products from the brain. This accumulation of potentially toxic metabolites could exacerbate oxidative stress and vascular inflammation, contributing to the observed cardiovascular risk.

The striking risk elevations observed in Model 2 (Obese IHH vs Non-obese Control) reveal a synergistic interaction between IHH and obesity that amplifies cardiovascular risk beyond the sum of their individual effects. This synergy likely arises from the convergence of multiple pathophysiological processes, including adipokine dysregulation, neuroendocrine activation, and hemodynamic alterations. Recent work by Hornby et al. [54] demonstrates that IHH patients exhibit a distinct adipokine signature, with particularly elevated CSF leptin levels. The combination of systemic and central adipokine dysregulation may create a uniquely pro-inflammatory and pro-thrombotic state. Moreover, the evidence by Markey K et al. [55] suggests that IHH patients may have altered cortisol metabolism, potentially exacerbating the metabolic and cardiovascular consequences of obesity related Hypothalamic-Pituitary-Adrenal axis dysfunction.

The paradoxical findings regarding type 2 diabetes risk in our study—elevated in obese IHH patients but reduced in non-obese IHH patients compared to obese controls—challenge our current understanding of metabolic risk in IHH. This observation may be explained by the concept of "metabolic flexibility" proposed by Goodpaster and Sparks [56]. In non-obese IHH patients, the altered androgen metabolism and potential changes in adipose tissue function may confer a degree of metabolic protection. The evidence by Mariniello et al. [57] on androgen effects on adipose tissue suggests that certain androgen profiles can enhance insulin sensitivity and improve glucose uptake in adipocytes. The specific androgen milieu in IHH may thus have differential effects depending on the overall metabolic context. Conversely, in obese IHH patients, this potential metabolic benefit may be overwhelmed by the profound insulin resistance and chronic inflammation associated with obesity. The interaction between obesity-related metabolic dysfunction and IHH-specific neuroendocrine perturbations may create a "perfect storm" for accelerated progression to type 2 diabetes [57].

Our findings necessitate a paradigm shift in the approach to cardiovascular risk management in IHH patients. We propose a multi-tiered strategy that includes enhanced risk stratification, targeted interventions, personalized metabolic management, and neuroendocrine modulation. The development of IHH-specific cardiovascular risk calculators that incorporate novel biomarkers such as CSF androgen levels, adipokine profiles, and measures of intracranial pressure dynamics could significantly improve risk assessment in this population. Exploration of IHH-specific pharmacological interventions that address the unique pathophysiology of cardiovascular risk in this population is warranted. For example, the potential use of selective androgen receptor modulators (SARMs) to mitigate the adverse cardiovascular effects of androgen excess while preserving potential metabolic benefits merits investigation.

Future research directions should include longitudinal studies employing advanced imaging techniques to elucidate the temporal relationship between IHH onset, progression, and cardiovascular remodeling. Multi-omics approaches integrating genomics, transcriptomics, and metabolomics could unravel the molecular mechanisms underlying the observed synergy between IHH and obesity in cardiovascular risk. Interventional trials exploring the cardiovascular

impact of IHH-specific treatments, including the potential cardioprotective effects of CSF diversion procedures or novel pharmacological agents targeting ICP regulation, are crucial. Additionally, investigation of sex-specific aspects of cardiovascular risk in IHH is essential, given the strong female predominance of the condition and the potential interaction with sex hormones.

The findings from our study reveal a complex, multifaceted relationship between IHH, obesity, and cardiovascular risk that challenges existing paradigms and opens new frontiers in personalized medicine. The independent risk conferred by IHH, the synergistic effects with obesity, and the paradoxical metabolic findings underscore the need for a nuanced, mechanism-based approach to cardiovascular risk management in this unique patient population. As we continue to unravel the intricate pathophysiology of IHH, we move closer to developing targeted interventions that may not only alleviate the neurological symptoms of the condition but also mitigate its long-term cardiovascular consequences. The implications of our findings extend beyond IHH, offering potential insights into the broader interplay between neuroendocrine function, metabolic regulation, and cardiovascular health. The methodology of our paper has several limitations, at first the approach assumes that the HR and the values provided from the original data and the HR for obesity remains constant over the 13-year period and its applicable to both the IHH group and control group. Secondly, it assumes that the effect of obesity on the events is independent of IHH status in each patient. Thirdly, the predicted events are based on the average HR for obesity from the current literature, which may not be fully representative of the study population in larger populations or another cohort. Also, the adjusted for IHH independent from obesity should be interpreted with caution, as it is an estimation based on the available data and assumptions. To further validate the findings, it would be better to perform tailored individual-level data analysis based on BMI subgroup analysis and sensitivity tests for IHH patients and counting for other potential confounding variables in the cohort. Additionally, conducting a prospective study that directly compares IHH patients with normal weight controls would provide more comprehensive evidence for the independent effect of IHH on the proposed events.

## **5. Conclusions:**

Our study provides compelling evidence for a nuanced relationship between idiopathic intracranial hypertension (IHH), obesity, and cardiovascular risk. Through innovative statistical modeling, we have disentangled the independent effects of IHH from those of obesity, revealing a complex interplay with significant clinical implications. Our findings demonstrate that IHH confers substantial cardiovascular risk beyond that attributable to obesity alone. The consistent elevation of risk ratios across obesity-stratified models suggests an intrinsic pathophysiological process in IHH that exacerbates cardiovascular vulnerability. This aligns with emerging research on neuroendocrine perturbations in IHH, particularly the unique androgen metabolic signature recently identified in cerebrospinal fluid. The striking synergy between IHH and obesity in

amplifying cardiovascular risk, as evidenced by our Model 2 results, underscores the critical importance of addressing both conditions concurrently. This synergistic effect likely arises from the convergence of multiple pathways, including adipokine dysregulation, altered intracranial fluid dynamics, and systemic metabolic dysfunction. Our paradoxical findings regarding type 2 diabetes risk—elevated in obese IHH patients but reduced in non-obese IHH patients compared to obese controls—challenge current understanding and suggest a complex metabolic phenotype in IHH. This observation may reflect the concept of "metabolic flexibility" and warrants further investigation into the differential effects of IHH-specific neuroendocrine changes in varying metabolic contexts. These results necessitate a paradigm shift in IHH management, calling for a multi-faceted approach that extends beyond intracranial pressure control to encompass comprehensive cardiovascular risk mitigation. We propose the development of IHH-specific cardiovascular risk calculators incorporating novel biomarkers and the exploration of targeted interventions addressing the unique pathophysiology of cardiovascular risk in this population. Our study's limitations, including assumptions about constant hazard ratios and obesity effects, underscore the need for further research. Prospective studies directly comparing IHH patients with normal-weight controls and employing advanced multi-omics approaches will be crucial to validating and extending our findings.

**Conflicts of Interest:** N/A

**IRB Approval:** N/A

**Funding Source:** N/A

**Ethical Approvals:** N/A

**Consent for Participation:** N/A

**Consent to Publish:** N/A

**Data Availability Statement:** N/A

## References:

1. Mollan, S.P., et al., *Idiopathic intracranial hypertension: consensus guidelines on management*. 2018. **89**(10): p. 1088-1100.
2. Mollan, S.P., et al., *The expanding burden of idiopathic intracranial hypertension*. Eye (Lond), 2019. **33**(3): p. 478-485.
3. Daniels, A.B., et al., *Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri)*. Am J Ophthalmol, 2007. **143**(4): p. 635-41.
4. Adderley, N.J., et al., *Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom*. JAMA Neurol, 2019. **76**(9): p. 1088-1098.
5. Strazzullo, P., et al., *Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants*. Stroke, 2010. **41**(5): p. e418-26.
6. O'Reilly, M.W., et al., *A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics*. JCI Insight, 2019. **4**(6).
7. Zhao, L., et al., *Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis*. Oncotarget, 2016. **7**(23): p. 33715-21.
8. de Groot, P.C., et al., *PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis*. Hum Reprod Update, 2011. **17**(4): p. 495-500.
9. Fleiss, J.L., B. Levin, and M.C. Paik, *Statistical methods for rates and proportions*. 2013: john wiley & sons.
10. Greenland, S.J.E., *Quantifying biases in causal models: classical confounding vs collider-stratification bias*. 2003. **14**(3): p. 300-306.
11. Schneeweiss, S.J.P. and d. safety, *Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics*. 2006. **15**(5): p. 291-303.
12. Hernan, M. and J. Robins, *Causal inference: What if. boca raton: Chapman & hill/crc*. 2020.
13. Lin, D.Y., B.M. Psaty, and R.A.J.B. Kronmal, *Assessing the sensitivity of regression results to unmeasured confounders in observational studies*. 1998: p. 948-963.
14. Schmiegelow, M.D., et al., *Prepregnancy obesity and associations with stroke and myocardial infarction in women in the years after childbirth: a nationwide cohort study*. Circulation, 2014. **129**(3): p. 330-7.
15. Li, T.Y., et al., *Obesity as compared with physical activity in predicting risk of coronary heart disease in women*. Circulation, 2006. **113**(4): p. 499-506.
16. Song, X., et al., *Obesity attenuates gender differences in cardiovascular mortality*. Cardiovasc Diabetol, 2014. **13**: p. 144.
17. Dikaiou, P., et al., *Obesity, overweight and risk for cardiovascular disease and mortality in young women*. Eur J Prev Cardiol, 2021. **28**(12): p. 1351-1359.

18. Medina-Inojosa, J.R., et al., *Relation of Waist-Hip Ratio to Long-Term Cardiovascular Events in Patients With Coronary Artery Disease*. *Am J Cardiol*, 2018. **121**(8): p. 903-909.
19. Kip, K.E., et al., *Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study*. *Circulation*, 2004. **109**(6): p. 706-13.
20. Czernichow, S., et al., *Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk?: evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies*. *Obes Rev*, 2011. **12**(9): p. 680-7.
21. Kurth, T., et al., *Prospective study of body mass index and risk of stroke in apparently healthy women*. *Circulation*, 2005. **111**(15): p. 1992-8.
22. Sánchez-Iñigo, L., et al., *Risk of incident ischemic stroke according to the metabolic health and obesity states in the Vascular-Metabolic CUN cohort*. *Int J Stroke*, 2017. **12**(2): p. 187-191.
23. Zahn, K., et al., *Body fat distribution and risk of incident ischemic stroke in men and women aged 50 to 74 years from the general population. The KORA Augsburg cohort study*. *PLoS One*, 2018. **13**(2): p. e0191630.
24. Chen, M.Q., et al., *Sex Differences of Combined Effects Between Hypertension and General or Central Obesity on Ischemic Stroke in a Middle-Aged and Elderly Population*. *Clin Epidemiol*, 2021. **13**: p. 197-206.
25. Chaudhary, D., et al., *Obesity and mortality after the first ischemic stroke: Is obesity paradox real?* *PLoS One*, 2021. **16**(2): p. e0246877.
26. Horn, J.W., et al., *Obesity and Risk for First Ischemic Stroke Depends on Metabolic Syndrome: The HUNT Study*. *Stroke*, 2021. **52**(11): p. 3555-3561.
27. Yatsuya, H., et al., *Body mass index and risk of stroke and myocardial infarction in a relatively lean population: meta-analysis of 16 Japanese cohorts using individual data*. *Circ Cardiovasc Qual Outcomes*, 2010. **3**(5): p. 498-505.
28. Cordola Hsu, A.R., et al., *Metabolically Healthy/Unhealthy Overweight/Obesity Associations With Incident Heart Failure in Postmenopausal Women: The Women's Health Initiative*. *Circ Heart Fail*, 2021. **14**(4): p. e007297.
29. Padwal, R., et al., *The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data*. *Int J Obes (Lond)*, 2014. **38**(8): p. 1110-4.
30. Halldin, A.K., et al., *Obesity in Middle Age Increases Risk of Later Heart Failure in Women-Results From the Prospective Population Study of Women and H70 Studies in Gothenburg, Sweden*. *J Card Fail*, 2017. **23**(5): p. 363-369.
31. Mørkedal, B., et al., *Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway*. *J Am Coll Cardiol*, 2014. **63**(11): p. 1071-8.
32. Kawada, T., *Metabolically healthy obesity and cardiovascular events: A risk of obesity*. *Diabetes Obes Metab*, 2022. **24**(4): p. 763.
33. Chandramouli, C., et al., *Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study*. *PLoS Med*, 2019. **16**(9): p. e1002916.
34. Kenchaiah, S., et al., *Pericardial Fat and the Risk of Heart Failure*. *J Am Coll Cardiol*, 2021. **77**(21): p. 2638-2652.

35. Lee, S.K., et al., *Obesity phenotype and incident hypertension: a prospective community-based cohort study*. *J Hypertens*, 2013. **31**(1): p. 145-51.
36. Kabootari, M., et al., *Sex specific impact of different obesity phenotypes on the risk of incident hypertension: Tehran lipid and glucose study*. *Nutr Metab (Lond)*, 2019. **16**: p. 16.
37. Lewandowska, M., B. Więckowska, and S. Sajdak, *Pre-Pregnancy Obesity, Excessive Gestational Weight Gain, and the Risk of Pregnancy-Induced Hypertension and Gestational Diabetes Mellitus*. *J Clin Med*, 2020. **9**(6).
38. Nurdiantami, Y., et al., *Association of general and central obesity with hypertension*. *Clin Nutr*, 2018. **37**(4): p. 1259-1263.
39. Curhan, G.C., et al., *Birth weight and adult hypertension and obesity in women*. *Circulation*, 1996. **94**(6): p. 1310-5.
40. Gus, M., et al., *Association between different measurements of obesity and the incidence of hypertension*. *Am J Hypertens*, 2004. **17**(1): p. 50-3.
41. Behboudi-Gandevani, S., et al., *Cardiometabolic risks in polycystic ovary syndrome: long-term population-based follow-up study*. *Fertil Steril*, 2018. **110**(7): p. 1377-1386.
42. Freedman, D.S., et al., *Relation of body fat distribution to ischemic heart disease. The National Health and Nutrition Examination Survey I (NHANES I) Epidemiologic Follow-up Study*. *Am J Epidemiol*, 1995. **142**(1): p. 53-63.
43. Quesada, O., et al., *Body weight and physical fitness in women with ischaemic heart disease: does physical fitness contribute to our understanding of the obesity paradox in women?* *Eur J Prev Cardiol*, 2022. **29**(12): p. 1608-1614.
44. Okamura, T., et al., *Ectopic fat obesity presents the greatest risk for incident type 2 diabetes: a population-based longitudinal study*. *Int J Obes (Lond)*, 2019. **43**(1): p. 139-148.
45. Lee, D.H., et al., *Comparison of the association of predicted fat mass, body mass index, and other obesity indicators with type 2 diabetes risk: two large prospective studies in US men and women*. *Eur J Epidemiol*, 2018. **33**(11): p. 1113-1123.
46. Park, S.K., et al., *Longitudinally evaluated the relationship between body fat percentage and the risk for type 2 diabetes mellitus: Korean Genome and Epidemiology Study (KoGES)*. *Eur J Endocrinol*, 2018. **178**(5): p. 513-521.
47. Carey, V.J., et al., *Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study*. *Am J Epidemiol*, 1997. **145**(7): p. 614-9.
48. Anagnostis, P., et al., *Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies*. *Endocrine*, 2021. **74**(2): p. 245-253.
49. Sluik, D., et al., *Associations between general and abdominal adiposity and mortality in individuals with diabetes mellitus*. *Am J Epidemiol*, 2011. **174**(1): p. 22-34.
50. Yang, J., et al., *Modifiable risk factors and long term risk of type 2 diabetes among individuals with a history of gestational diabetes mellitus: prospective cohort study*. *Bmj*, 2022. **378**: p. e070312.
51. Hong, S., et al., *Association Between Obesity and Cardiovascular Disease in Elderly Patients With Diabetes: A Retrospective Cohort Study*. *J Clin Endocrinol Metab*, 2022. **107**(2): p. e515-e527.
52. Duckles, S.P. and V.M. Miller, *Hormonal modulation of endothelial NO production*. *Pflugers Arch*, 2010. **459**(6): p. 841-51.

53. Wardlaw, J.M., et al., *Perivascular spaces in the brain: anatomy, physiology and pathology*. Nat Rev Neurol, 2020. **16**(3): p. 137-153.
54. Hornby, C., et al., *Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention*. J Neuroophthalmol, 2018. **38**(4): p. 522-530.
55. Markey, K., et al., *11 $\beta$ -Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial*. Brain Commun, 2020. **2**(1): p. fcz050.
56. Goodpaster, B.H. and L.M. Sparks, *Metabolic Flexibility in Health and Disease*. Cell Metab, 2017. **25**(5): p. 1027-1036.
57. Mariniello, B., et al., *Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome*. Eur J Endocrinol, 2006. **155**(3): p. 435-41.



## **Figures Legend:**

**Figure 1:** Model 1 – Obese IHH vs Obese Control Forest Plot.

**Figure 2:** Model 2 – Obese IHH vs Non-Obese Control Forest Plot.

**Figure 3:** Model 3 – Non-Obese IHH vs Obese Control Forest Plot.

**Figure 4:** Model 4 – Non-Obese IHH vs Non-Obese Control Forest Plot.

## **Tables Legend:**

**Table 1:** Baseline Characteristics of the Included Individuals in the Original Study.

**Table 2:** Risk Contribution Calculations According to Different Hazard Regression Models.

**Table 1:** Baseline Characteristics of the Included Individuals in the Original Study.

Variable	Number, (%)	
	Women With IHH (Exposed Group)	Women Without IHH (Control Group)
Population	2760 (9.2)	27 125 (90.8)
Incident Cohort	1331 (48.2)	12 679 (46.7)
Population Aged < 60 y	2709 (98.1)	25 811 (95.2)
Age, Median (IQR), y	32.1 (25.62-42.00)	32.1 (25.71-42.06)
<b>Townsend Deprivation Quintile</b>		
1 (Least deprived)	361 (13.1)	4268 (15.7)
2	381 (13.8)	4397 (16.2)
3	532 (19.3)	5174 (19.1)
4	538 (19.5)	5122 (18.9)
5 (Most deprived)	454 (16.5)	4134 (15.2)
Missing data	494 (17.9)	4030 (14.9)
<b>Smoking Status</b>		
Nonsmoker	1284 (46.5)	15 058 (55.5)
Ex-smoker	502 (18.2)	4573 (16.9)
Smoker	849 (30.8)	6134 (22.6)
Missing data	125 (4.5)	1360 (5.0)
BMI, median (IQR)	34.80 (29.30-40.30)	34.30 (29.00-39.70)
<b>Body Mass Index (BMI)</b>		
<25	246 (8.9)	2561 (9.4)
25-30	416 (15.1)	4203 (15.5)
>30	1728 (62.6)	16 514 (60.9)
Missing data	370 (13.4)	3847 (14.2)
Current lipid prescription	180 (6.5)	1572 (5.8)
Migraine	580 (21.0)	3247 (11.9)
<b>Outcomes at Baseline</b>		
Heart Failure	8 (0.3)	58 (0.2)
Ischemic Heart Disease (IHD)	35 (1.3)	245 (0.9)
Ischemic Stroke / Transient Ischemic Attack (TIA)	46 (1.7)	189 (0.7)

<b>Hypertension</b>	380 (13.8)	2500 (9.2)
<b>Type 2 Diabetes Mellitus</b>	130 (4.7)	1425 (5.2)

**Table 2:** Risk Contribution Calculations According to Different Hazard Regression Models.


<i>Outcome</i>	<i>Women With IIH (Exposed Group)</i>	<i>P-Value</i>	<i>Women Without IIH (Control Group)</i>
<b>Composite CVD</b>			
Population, No.	2613	NA	26 356
Outcome events, No. (%)	68 (2.5)	NA	328 (1.2)
Person-years	12 809	NA	132 930
Crude incidence rate per 1000 person-years	5.31	NA	2.47
Follow-up, median (IQR), y	3.50 (1.34-7.11)	NA	3.72 (1.51-7.39)
Adjusted HR (95% CI)			
Model 1	<b>2.15 [1.66 - 2.79]</b>	<b>&lt;.001**</b>	NA
Model 2	<b>6.19 [4.58 - 8.36]</b>	<b>&lt;.001**</b>	NA
Model 3	0.76 [0.50 - 1.15]	0.2	NA
Model 4	<b>2.18 [1.41 - 3.39]</b>	<b>&lt;.001**</b>	NA
<b>Heart Failure</b>			
Population, No.	2735	NA	26 989
Outcome events, No. (%)	17 (0.6)	NA	78 (0.3)
Person-years	13 445	NA	136 357
Crude incidence rate per 1000 person-years	1.26	NA	0.57
Follow-up, median (IQR), y	3.58 (1.38-7.26)	NA	3.77 (1.52-7.50)
Adjusted HR (95% CI)			
Model 1	<b>2.21 [1.31 - 3.74]</b>	<b>&lt;.001**</b>	NA
Model 2	<b>5.75 [3.17 - 10.42]</b>	<b>&lt;.001**</b>	NA
Model 3	0.91 [0.42 - 1.97]	0.81	NA
Model 4	<b>2.37 [1.04 -</b>	<b>0.04*</b>	NA

	<b>5.39]</b>		
<b>Ischemic Heart Disease</b>			
Population, No.	2698	NA	26 749
Outcome events, No. (%)	27 (0.9)	NA	131 (0.5)
Person-years	13 216	NA	134 521
Crude incidence rate per 1000 person-years	2.04	NA	0.97
Follow-up, median (IQR), y	3.56 (1.37-7.20)	NA	3.73 (1.51-7.42)
Adjusted HR (95% CI)			
Model 1	<b>2.10 [1.39 - 3.17]</b>	<b>&lt;.001**</b>	NA
Model 2	<b>3.76 [2.42 - 5.85]</b>	<b>&lt;.001**</b>	NA
Model 3	1.17 [0.68 - 1.99]	0.57	NA
Model 4	<b>2.09 [1.20 - 3.65]</b>	<b>&lt;.01*</b>	NA
<b>Stroke/TIA</b>			
Population, No.	2674	NA	26 755
Outcome events, No. (%)	40 (1.5)	NA	181 (0.7)
Person-years	13 115	NA	135 271
Crude incidence rate per 1000 person-years	3.05	NA	1.34
Follow-up, median (IQR), y	3.51 (1.34-7.17)	NA	3.76 (1.52-7.47)
Adjusted HR (95% CI)			
Model 1	<b>2.28 [1.62 - 3.21]</b>	<b>&lt;.001**</b>	NA
Model 2	<b>3.93 [2.73 - 5.66]</b>	<b>&lt;.001**</b>	NA
Model 3	1.37 [0.89 - 2.09]	0.15	NA
Model 4	<b>2.36 [1.51 - 3.67]</b>	<b>&lt;.001**</b>	NA
<b>Hypertension</b>			
Population, No.	2232	NA	23 566
Outcome events, No. (%)	148 (6.2)	NA	1059 (4.3)
Person-years	10 505	NA	115 800
Crude incidence rate per 1000 person-years	14.09	NA	9.15
Follow-up, median (IQR), y	3.20 (1.26-6.40)	NA	3.48 (1.43-6.94)
Adjusted HR (95% CI)			
Model 1	<b>1.54 [1.30 -</b>	<b>&lt;.001**</b>	NA


	<b>1.83]</b>		
Model 2	<b>3.22 [2.68 - 3.86]</b>	<b>&lt;.001**</b>	NA
Model 3	<b>0.77 [0.61 - 0.97]</b>	<b>0.03*</b>	NA
Model 4	<b>1.61 [1.26 - 2.05]</b>	<b>&lt;.001**</b>	NA
<b>Type 2 Diabetes</b>			
Population, No.	2510	NA	24 901
Outcome events, No. (%)	120 (4.6)	NA	799 (3.1)
Person-years	12 300	NA	125 947
Crude incidence rate per 1000 person-years	9.76	NA	6.34
Follow-up, median (IQR), y	3.49 (1.34-6.94)	NA	3.62 (1.47-7.27)
Adjusted HR (95% CI)			
Model 1	<b>1.54 [1.27 - 1.86]</b>	<b>&lt;.001**</b>	NA
Model 2	<b>6.14 [4.90 - 7.70]</b>	<b>&lt;.001**</b>	NA
Model 3	<b>0.40 [0.28 - 0.57]</b>	<b>&lt;.001**</b>	NA
Model 4	<b>1.59 [1.09 - 2.32]</b>	<b>0.02*</b>	NA

\* Denotes statistical significance, \*\* Denotes high statistical significance

# Model 1: Obese I1H vs Obese Control




## Model 2: Obese I1H vs Non-obese Control





### Model 3: Non-obese IIH vs Obese Control



# Model 4: Non-obese IIH vs Non-obese Control

